Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)

K Krogsgaard; E Christensen; N Bindslev; S Schalm; P K Andersen; H Ring-Larsen

doi:10.1016/S0168-8278(96)80281-9

Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)

K Krogsgaard, E Christensen, N Bindslev, S Schalm, P K Andersen, H Ring-Larsen

Copenhagen Trial Unit

16 Citations (Scopus)

Abstract

Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.

Original language	English
Journal	Journal of Hepatology
Volume	25
Issue number	6
Pages (from-to)	795-802
Number of pages	8
ISSN	0168-8278
DOIs	https://doi.org/10.1016/S0168-8278(96)80281-9
Publication status	Published - Dec 1996

Keywords

Adolescent
Adult
Aged
Antiviral Agents
Child
Chronic Disease
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Hepatitis B
Hepatitis B Antibodies
Hepatitis B e Antigens
Hepatitis B virus
Humans
Interferon-alpha
Male
Middle Aged
Randomized Controlled Trials as Topic
Regression Analysis
Treatment Outcome

Access to Document

10.1016/S0168-8278(96)80281-9

Cite this

@article{1b7578b44f744115a0f252d4b90cbc7d,

title = "Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)",

abstract = "Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.",

keywords = "Adolescent, Adult, Aged, Antiviral Agents, Child, Chronic Disease, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Hepatitis B, Hepatitis B Antibodies, Hepatitis B e Antigens, Hepatitis B virus, Humans, Interferon-alpha, Male, Middle Aged, Randomized Controlled Trials as Topic, Regression Analysis, Treatment Outcome",

author = "K Krogsgaard and E Christensen and N Bindslev and S Schalm and Andersen, \{P K\} and H Ring-Larsen",

year = "1996",

month = dec,

doi = "10.1016/S0168-8278(96)80281-9",

language = "English",

volume = "25",

pages = "795--802",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)

AU - Krogsgaard, K

AU - Christensen, E

AU - Bindslev, N

AU - Schalm, S

AU - Andersen, P K

AU - Ring-Larsen, H

PY - 1996/12

Y1 - 1996/12

N2 - Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.

AB - Alpha interferon (IFN) is an established treatment of chronic hepatitis B. The effect has been shown to be dose related, recommended dose regimens being associated with a doubling of the spontaneous, baseline HBeAg to anti-HBe seroconversion rate. However, the efficacy of IFN treatment in relation to the dose of IFN actually received remains to be established. The aim of this study was to estimate the relative efficacy of IFN as a function of the cumulative IFN dose. In addition we determined if and when a patient returns to his baseline chance of seroconversion after stopping IFN therapy.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antiviral Agents

KW - Child

KW - Chronic Disease

KW - Dose-Response Relationship, Drug

KW - Female

KW - Follow-Up Studies

KW - Hepatitis B

KW - Hepatitis B Antibodies

KW - Hepatitis B e Antigens

KW - Hepatitis B virus

KW - Humans

KW - Interferon-alpha

KW - Male

KW - Middle Aged

KW - Randomized Controlled Trials as Topic

KW - Regression Analysis

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/0030472814

U2 - 10.1016/S0168-8278(96)80281-9

DO - 10.1016/S0168-8278(96)80281-9

M3 - Journal article

C2 - 9007705

SN - 0168-8278

VL - 25

SP - 795

EP - 802

JO - Journal of Hepatology

JF - Journal of Hepatology

IS - 6

ER -

Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this